Patients undergoing coronary revascularisation: A missed opportunity for secondary prevention?

Postgraduate Medical Journal

Volumn 81, Issue 956, 2005, Pages 401-403

  Fox, D J ^a   Kibiro, M ^a   Eichhofer J ^a   Curzen, N P ^b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; PRESCRIPTION; RETROSPECTIVE STUDY; SECONDARY PREVENTION; STATISTICAL ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CORONARY ARTERY BYPASS; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 20644463210     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.023861     Document Type: Article

References (19)

1. Department of Health. National Service Framework for coronary heart disease. London: HMSO, 2000.
2. Archbold RA, Curzen NP. The role of revascularisation in the treatment of acute coronary syndromes: who should you refer? Clin Med 2004;4:32-5.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
5. Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularised patients with average cholesterol concentrations. J Am Coll Cardiol 1999;34:106-12.
6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
7. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
8. Pfeffer MA, Braunwald E, Moye LA, et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
9. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
10. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
11. Archbold A, Zaman A, Curzen N, et al. Prescribing of angiotensin enzyme inhibitors and statins after CABG: a missed opportunity for secondary prevention. British Journal of Cardiology 2003;10:36-44.
12. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. 1. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
13. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71-86.
14. Freemantle N, Cleland J, Young P, et al. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.
15. Gottlieb SS, McCarter RJ, Vogel RA. Effects of β blockade on mortality among low and high risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
16. Doughty RN, Rodgers A, Sharpe N, et al. Effects of β blocker therapy on mortality in patients with heart failure. A systematic overview of randomised controlled trials. Eur Heart J 1997;18:560-5.
17. Aspire Steering Group. A British Cardiac Society survey of the potential for secondary prevention of coronary disease: ASPIRE (action on secondary prevention through intervention to reduce events). Principal results. Heart 1996;75:334-42.
18. Fox KM. European triol on reduction of cardiac events with perindopril in stable coronary artery disease investigators (the EUROPA study). Lancet 2003;362:782-8.
19. Aronow HD, Novaro GM, Lauer MS, et al. In hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long term utilisation. Arch Intern Med 2003;163:2576-82.